天士力(600535.SH)子公司TSL2109胶囊获得药物临床试验批准通知书

Core Viewpoint - Tianshili (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd. (referred to as "Jiangsu Diyi"), has received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors [1] Group 1 - TSL2109 capsules are a novel dual-target small molecule inhibitor developed in collaboration with China Pharmaceutical University [1] - The drug works by selectively inhibiting downstream signaling pathways of the two targets, blocking the tumor cell cycle and inducing tumor cell apoptosis [1] - TSL2109 aims to synergistically kill tumor cells through its dual-target mechanism [1]